Nivolumab plus ipilimumab plus chemo vs pembrolizumab plus chemo in PD-L1 negative metastatic NSCLC patients: comparative effectiveness using the target trial emulation framework.

ENCePP Code of conduct

Yes

Data sources

• Data source(s), other:
  Dutch Medication Audit (DMA);; Dutch Lung Cancer Audit - Lungcarcinoma (DLCA-L).
• Data sources (types):
  Cancer registry

  Disease registry

  Drug registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown

Procedures

No information provided.